Tanzania Medicines and Medical Devices Authority Ban on Levamisole-Containing Veterinary Products

The Tanzania Medicines and Medical Devices Authority (TMDA) has issued a comprehensive ban on all veterinary medicinal products containing Levamisole as an active pharmaceutical ingredient. Effective from June 24, 2026, the regulatory action mandates an immediate cessation of manufacturing, importation, distribution, and sale of these products. The ban stems from scientific evidence indicating serious adverse events in animals when Levamisole is administered in higher than recommended doses or for prolonged periods, coupled with concerns over drug residues in the food chain due to inadequate withdrawal period management. Importers and distributors are directed to initiate a market recall within 14 days, and all stakeholders in possession of such products must return them to TMDA offices, underscoring the Authority's commitment to public health and animal safety under the One Health approach.

The Tanzania Medicines and Medical Devices Authority (TMDA), the principal regulatory body for medicines and medical devices in Tanzania, has announced a significant regulatory intervention impacting the veterinary sector. Effective June 24, 2026, the Authority has imposed a complete ban on the use, manufacture, importation, distribution, and sale of all veterinary medicinal products containing Levamisole as an active pharmaceutical ingredient (API). This decisive action is a direct response to growing concerns regarding the safety and efficacy of Levamisole-containing products and their potential impact on both animal health and public safety.

This ban represents a critical development for all stakeholders within Tanzania's livestock and pharmaceutical industries, including manufacturers, importers, distributors, veterinary professionals, and livestock keepers. The TMDA's directive is rooted in its mandate to safeguard public health and ensure the quality, safety, and efficacy of medicinal products available in the country. The move aligns with global best practices in pharmacovigilance and the overarching 'One Health' approach, which recognizes the interconnectedness of human, animal, and environmental health.

This article will delve into the statutory and scientific underpinnings of the ban, analyze its immediate and long-term implications for legal and veterinary practitioners, and outline the compliance requirements for all affected parties. It aims to provide a clear understanding of the regulatory landscape shaped by this prohibition and the necessary steps for adherence.

The Tanzania Medicines and Medical Devices Authority (TMDA) operates under the authority of the Tanzania Medicines and Medical Devices Act, Chapter 219 R.E. 2023 (formerly the Tanzania Food, Drugs and Cosmetics Act, Cap 219). This Act empowers the TMDA to regulate and control medicines, medical devices, herbal drugs, and poisons, ensuring their quality, safety, and efficacy for both human and veterinary use. The Authority's responsibilities include market authorization (registration), inspections, compliance monitoring, and robust pharmacovigilance activities to continuously assess the safety of products post-marketing.

Prior to this ban, veterinary medicinal products containing Levamisole were registered and widely used in Tanzania for the treatment and prevention of various worm infestations in livestock. Levamisole is known for its anthelmintic properties, acting as a cholinergic receptor agonist to cause neuromuscular paralysis in target parasites. However, its therapeutic use has always been accompanied by a limited safety margin, with the potential for intoxication if administered beyond standard doses.

The TMDA's regulatory framework also encompasses the registration and licensing of premises dealing with veterinary products, as well as guidelines for the submission of documentation for the registration of veterinary medicinal products. These foundational legal instruments provide the TMDA with the necessary powers to conduct assessments, identify risks, and implement regulatory actions, such as the current ban, to protect animal and public health.

The TMDA's decision to ban Levamisole-containing veterinary products is a direct outcome of a comprehensive assessment that revealed significant safety concerns. Scientific evidence gathered by the Authority indicates that when animals are administered Levamisole in doses higher than recommended or for prolonged periods, they develop serious adverse events. These include, but are not limited to, excessive salivation, hyperesthesia, muscle tremors, ataxia, head shaking, clonic convulsions, respiratory muscle paralysis, and in severe cases, asphyxia and death. This aligns with documented cases of Levamisole toxicosis in animals, which often manifest as cholinergic signs and can be fatal due to respiratory failure.

Beyond direct animal health risks, a primary driver for the ban is the concern over drug residues in the food chain. The TMDA highlighted the lack of adequate management of withdrawal periods by users, which increases the risk of Levamisole residues remaining in animal products destined for human consumption. This poses a direct public health risk, reinforcing the Authority's commitment to the 'One Health Approach,' which emphasizes the interconnectedness of human, animal, and environmental health. The potential for such residues to enter the food supply underscores the necessity of stringent regulatory control over veterinary pharmaceuticals.

The regulatory action is comprehensive, prohibiting all aspects of the product lifecycle for Levamisole-containing veterinary medicines. This includes manufacturing, importation, distribution, and sale within Tanzania. Importers and distributors were directed to cease distribution and supply immediately from the date of the notice (June 24, 2026) and to initiate a recall from the market within 14 days. Furthermore, applications for registration of such products will no longer be accepted, and no permits will be issued for their manufacturing, importation, distribution, or sale. Livestock keepers, traders, and other stakeholders currently in possession of these products are mandated to return them to TMDA headquarters or designated zone offices.

The TMDA's authority to implement such a ban is firmly established in the Tanzania Medicines and Medical Devices Act, Cap 219 R.E. 2023. Sections 59 and 60 of the Act, for instance, prohibit the sale of drugs that do not comply with prescribed requirements and the manufacture, sale, and distribution of undesirable drugs. The Authority's post-marketing surveillance and pharmacovigilance mechanisms, as outlined in its mandate, enable it to monitor product safety and take necessary regulatory steps when risks are identified. This proactive stance is consistent with international regulatory trends, where Levamisole's use in human medicine has also been restricted due to severe adverse effects like leukoencephalopathy, agranulocytosis, and vasculitis.

While the ban directly addresses the safety concerns associated with Levamisole, it also implicitly highlights broader challenges in veterinary drug stewardship within Tanzania. Reports indicate that a significant portion of livestock keepers may have limited access to professional veterinary services, potentially leading to misuse or improper administration of veterinary drugs, including inadequate adherence to withdrawal periods. The TMDA's action, therefore, serves not only as a product-specific ban but also as a reinforcement of the need for responsible drug use and adherence to regulatory guidelines across the livestock sector.

The TMDA's ban on veterinary medicinal products containing Levamisole marks a critical regulatory shift aimed at bolstering animal health and safeguarding public health in Tanzania. For legal practitioners advising clients in the pharmaceutical, veterinary, and livestock sectors, immediate attention to compliance is paramount. Importers and distributors must ensure the prompt cessation of supply and the complete recall of all affected products within the stipulated 14-day period from June 24, 2026. Failure to comply could result in significant legal and financial repercussions under the Tanzania Medicines and Medical Devices Act, Cap 219 R.E. 2023.

Veterinary professionals and livestock keepers are likewise urged to immediately discontinue the use of Levamisole-containing products and return existing stock to TMDA offices. This directive underscores the Authority's unwavering commitment to ensuring that only quality, safe, and efficacious medicinal products are available on the Tanzanian market, in line with the principles of the One Health Approach. Practitioners should closely monitor further guidance from the TMDA and advise clients on alternative, approved anthelmintic treatments to ensure continuity of animal health management while adhering to the new regulatory landscape.